Local view for "http://purl.org/linkedpolitics/eu/plenary/2005-09-06-Speech-2-368"

PredicateValue (sorted: default)
rdf:type
dcterms:Date
dcterms:Is Part Of
dcterms:Language
lpv:document identification number
"en.20050906.36.2-368"2
lpv:hasSubsequent
lpv:speaker
lpv:spokenAs
lpv:translated text
"Mr President, the regulation on the safety of medicinal products for paediatric use is a necessary and sensible alternative that puts an end to a long period of uncertainty surrounding medicinal products in the paediatric sector. The Commission’s proposal was well-balanced and was based on impact assessments. A six-month extension of patent protection as an incentive for pharmaceutical manufacturers is reasonable. This period is based on the results of the impact study and is a clear, fair basis for calculation for all manufacturers. I am pleased that a majority in Parliament supports this fixed period. Variable patent protection is impracticable and entails a considerable administrative burden. In addition, the duration of a patent must never be dependent on a product’s sales figures. The international competitive situation of the research-oriented pharmaceutical industry demands that we take a look at Europe’s attractiveness as a research destination. This is another reason why I see no material arguments in favour of the reduction in the fixed six-month period that is still under discussion."@en1

Named graphs describing this resource:

1http://purl.org/linkedpolitics/rdf/English.ttl.gz
2http://purl.org/linkedpolitics/rdf/Events_and_structure.ttl.gz
3http://purl.org/linkedpolitics/rdf/spokenAs.ttl.gz

The resource appears as object in 2 triples

Context graph